Physician profile
Jason E Watts
NPI 1083171326
$3,265.58
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.59 · 2022: $1,448 · 2023: $1,806.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,667.20 |
| Education | $138.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,585.46 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $306.88 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $243.69 | 2022-2023 | Austedo Xr, Uzedy |
| Lundbeck LLC | $204.21 | 2022-2023 | Rexulti |
| Alkermes, INC. | $153.58 | 2022-2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $136.21 | 2022-2023 | Invega Sustenna, Invega Trinza |
| Idorsia Pharmaceuticals US INC | $111.15 | 2022-2023 | Quviviq |
| Corium, LLC | $98.72 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $87.08 | 2022-2023 | Rexulti, Nuedexta, Abilify Maintena |
| Neurocrine Biosciences, INC. | $79.58 | 2022-2023 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $53.92 | 2022 | |
| Supernus Pharmaceuticals, INC. | $53.72 | 2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $51.24 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.33 | 2022-2023 | Trintellix |
| Indivior INC. | $26.20 | 2023 | Perseris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $16.41 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.20 | 2023 | Hetlioz, Fanapt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Watts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.